Myles Minter

Stock Analyst at William Blair

(1.41)
# 3,543
Out of 5,042 analysts
21
Total ratings
52.94%
Success rate
-3.14%
Average return

Stocks Rated by Myles Minter

Alector
Oct 22, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $1.50
Upside: -
Dianthus Therapeutics
Jul 2, 2025
Initiates: Outperform
Price Target: n/a
Current: $32.92
Upside: -
Immunic
Mar 25, 2025
Initiates: Outperform
Price Target: n/a
Current: $0.77
Upside: -
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $3.65
Upside: -
argenx SE
Nov 1, 2024
Upgrades: Outperform
Price Target: n/a
Current: $817.32
Upside: -
Korro Bio
Aug 14, 2024
Initiates: Outperform
Price Target: n/a
Current: $38.09
Upside: -
Neumora Therapeutics
Oct 10, 2023
Initiates: Outperform
Price Target: n/a
Current: $2.63
Upside: -
Arcturus Therapeutics Holdings
Jul 24, 2023
Initiates: Outperform
Price Target: $71
Current: $11.22
Upside: +532.80%
Moderna
Jul 24, 2023
Initiates: Market Perform
Price Target: n/a
Current: $26.74
Upside: -
Vertex Pharmaceuticals
May 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $421.39
Upside: -
Downgrades: Market Perform
Price Target: n/a
Current: $173.97
Upside: -
Upgrades: Outperform
Price Target: n/a
Current: $4.21
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $463.43
Upside: -
Upgrades: Outperform
Price Target: n/a
Current: $70.86
Upside: -
Initiates: Outperform
Price Target: $116
Current: $144.00
Upside: -19.44%